Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Net Cash Flow (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Net Cash Flow data on record, last reported at -$46.1 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 13.79% year-over-year to -$46.1 million; the TTM value through Dec 2025 reached $18.4 million, up 144.68%, while the annual FY2025 figure was $18.4 million, 144.68% up from the prior year.
  • Net Cash Flow reached -$46.1 million in Q4 2025 per AMPH's latest filing, down from $28.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $119.8 million in Q3 2023 and bottomed at -$126.3 million in Q4 2023.
  • Average Net Cash Flow over 5 years is $3.8 million, with a median of $3.7 million recorded in 2024.
  • The widest YoY moves for Net Cash Flow: up 1459.14% in 2023, down 10738.45% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $19.8 million in 2021, then crashed by 105.89% to -$1.2 million in 2022, then tumbled by 10738.45% to -$126.3 million in 2023, then skyrocketed by 67.93% to -$40.5 million in 2024, then decreased by 13.79% to -$46.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$46.1 million in Q4 2025, $28.6 million in Q3 2025, and $4.8 million in Q2 2025.